August 23, 2023
FDA sees the potential of Redx Pharma’s zelasudil for treatment of Idiopathic Pulmonary Fibrosis
Redx has received Orphan Drug Designation from the US Food and Drug Administration (FDA) for the potential treatment of Idiopathic Pulmonary Fibrosis (IPF) for Zelasudil, which is currently in a Phase 2a clinical study for IPF, with topline data expected in Q1 2024.
